Haleon (LON:HLN) Given Buy Rating at Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of Haleon (LON:HLN) in a report published on Friday,Digital Look reports. Jefferies Financial Group currently has a GBX 400 target price on the stock.

A number of other equities analysts have also recently commented on the company. Royal Bank Of Canada lifted their target price on Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft decreased their price target on Haleon from GBX 335 to GBX 320 and set a “sell” rating on the stock in a report on Wednesday, September 9th. Finally, Berenberg Bank raised their price target on Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of GBX 385.80.

Haleon Trading Up 0.7%

HLN opened at GBX 319.90 on Friday. The stock has a 50-day moving average of GBX 352.97 and a 200 day moving average of GBX 360.40. The company has a current ratio of 0.69, a quick ratio of 0.93 and a debt-to-equity ratio of 50.38. Haleon has a 12 month low of GBX 310.50 and a 12 month high of GBX 433.60. The firm has a market cap of £28.14 billion, a P/E ratio of 17.67, a P/E/G ratio of 1.49 and a beta of 0.24.

Haleon (LON:HLN) last issued its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. As a group, research analysts forecast that Haleon will post 19.50 EPS for the current year.

Haleon announced that its Board of Directors has initiated a stock buyback program on Thursday, October 29th that permits the company to repurchase £500 million in outstanding shares. This repurchase authorization permits the company to buy up to 1.8% of its shares through open market purchases. Share repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

Key Headlines Impacting Haleon

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon approved a £500 million share repurchase program, equivalent to as much as 1.8% of outstanding shares. The buyback could support earnings per share and signals that management views the shares as undervalued. Haleon Q3 Revenue Rises; Trims Annual Revenue Growth Outlook; Launches £500 Mln Share Buyback
• Positive Sentiment: Jefferies reaffirmed its buy rating and set a GBX 400 price target, implying substantial upside from recent trading levels and providing some support for the stock. Jefferies reaffirms Haleon buy rating
• Neutral Sentiment: Deutsche Bank upgraded Haleon to hold but reduced its price target to GBX 310 from GBX 320. The change reflects a more balanced view rather than a strongly bullish signal. Deutsche Bank Haleon rating update
• Neutral Sentiment: Institutional positioning was mixed, with some major investors adding Haleon shares while others reduced holdings. These moves may influence sentiment but do not establish a clear near-term direction.
• Negative Sentiment: Haleon reported third-quarter organic revenue growth of 2.6%, below expectations, and cut its 2026 organic revenue growth outlook to about 2.5% from a previous 3%–5% range. Weak cough, cold and flu demand in North America, disruption to Centrum products in China, and a planned Brazil go-to-market change contributed to the downgrade. Haleon drops after Q3 sales miss and lower 2026 growth outlook

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.